Information Provided By:
Fly News Breaks for March 9, 2018
BIOS
Mar 9, 2018 | 09:09 EDT
Barrington analyst Michael Petusky says BioScrip shares should be bought now following the 15.5% selloff on the company's Q4 results. BioScrip reported "strong" Q4 results, and the investment decisions weighing on the 2018 outlook make sense, Petusky tells investors in a research note. He maintains an Outperform rating on the shares with a $3.50 price target.
News For BIOS From the Last 2 Days
There are no results for your query BIOS